Among various anti-CSC strategies, the ability of histone deacetylase (HDAC) inhibitors, alone or in combination therapy, to decrease tumor aggressiveness by eradicating CSCs is intriguing [27,28,29]. The gene discussed is HDAC9; the disease is neoplasm.